Treatment and Outcomes of Ewing Sarcoma in Turkish Adults: A Single Centre Experience |
Seker, Mehmet Metin
(Department of Medical Oncology, Cumhuriyet University Medical Faculty)
Kos, Tugba (Department of Medical Oncology, Manisa State Hospital) Ozdemir, Nuriye (Department of Medical Oncology, Numune Education and Research Hospital) Seker, Ayse (Department of Medical Oncology, Mutki State Hospital) Aksoy, Sercan (Department of Medical Oncology, Hacettepe University Cancer Institute) Uncu, Dogan (Department of Medical Oncology, Numune Education and Research Hospital) Zengin, Nurullah (Department of Medical Oncology, Numune Education and Research Hospital) |
1 | Baldini, EH, Demetri GD, Fletcher CD, et al (1999). Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg, 230, 79-86. DOI |
2 | Barbieri E, Emiliani E, Zini G, et al (1990). Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int J Radiat Oncol Biol Phys, 19, 1165-70. DOI |
3 | Collier AB, 3rd Simpson L, Monteleone P (2011). Cutaneous Ewing sarcoma: report of 2 cases and literature review of presentation, treatment, and outcome of 76 other reported cases. J Pediatr Hematol Oncol, 33, 631-4. DOI ScienceOn |
4 | Cotterill SJ, Ahrens S, Paulussen M, et al (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol, 18, 3108-14. |
5 | Saeter G (2007). Ewing's sarcoma of bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 18, 79-80. |
6 | Kushner BH, Meyers PA (2001). How effective is dose-intensive/ myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol, 19, 870-80. |
7 | Obata H, Ueda T, Kawai A, et al (2007). Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study. Cancer, 109, 767-75. DOI ScienceOn |
8 | Oberlin O, Deley MC, Bui BN, et al (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer, 85, 1646-54. DOI ScienceOn |
9 | Schwartz GK, Tap WD, Qin LX, et al (2013). Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol, 14 371-82. DOI ScienceOn |
10 | Scurr M, Judson I (2006). How to treat the Ewing's family of sarcomas in adult patients. Oncologist, 11, 65-72. DOI ScienceOn |
11 | Shannon Orr W, Denbo JW, Billups CA, et al (2012). Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol, 19, 3816-22. DOI |
12 | Grier HE, Krailo MD, Tarbell NJ, et al (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med, 348, 694-701. DOI ScienceOn |
13 | Gupta AA, Pappo A, Saunders N, et al (2010). Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer, 116, 3189-94. DOI ScienceOn |
14 | Fizazi K, Dohollou N, Blay JY, et al (1998). Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol, 16, 3736-43. |
15 | Granowetter L, Womer R, Devidas M, et al (2009). Doseintensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol, 27, 2536-41. DOI ScienceOn |
16 | Iwamoto Y (2007). Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol, 37, 79-89. DOI ScienceOn |
17 | Juergens H, Daw NC, Geoerger B, et al (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol, 29, 4534-40. DOI |
18 | Jurgens, H, U Dirksen (2011). Ewing sarcoma treatment. Eur J Cancer, 47, 366-7. |
19 | Kolb EA, Kushner BH, Gorlick R, et al (2003). Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 21, 3423-30. DOI ScienceOn |
20 | Jurgens H, Exner U (1988). Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer, 61, 23-32. DOI |
21 | Applebaum MA, Worch J, Matthay KK, et al (2011). Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer, 117, 3027-32. DOI ScienceOn |
22 | Bacci G, Ferrari S, Comandone A, et al (2000). Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol, 39, 111-6. DOI |
23 | Tap WD, Demetri G, Barnette P, et al (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol, 30, 1849-56. DOI ScienceOn |
24 | van Doorninck JA, Ji L, Schaub B, et al (2010). Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol, 28, 1989-94. DOI ScienceOn |
25 | Bacci G, Dallari D, McDonald D, et al (1989). Neoadjuvant chemotherapy for localized Ewing's sarcoma of the extremities: preliminary results of a protocol which uses surgery (alone or followed by radiotherapy) for local control. Tumori, 75, 456-62. |
26 | Balamuth N J, Womer RB (2010). Ewing's sarcoma. Lancet Oncol, 11, 184-92. DOI ScienceOn |
27 | Subbiah V, Anderson P, Lazar AJ, et al (2009). Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol, 10, 126-40. DOI ScienceOn |